Pascal Egloff

Pascal Egloff

Auto-generated profile, based on publicly available information

Pascal Egloff

Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2020 in Nature
Verified
Journal Article
Closed access
PDF file
FAFabian M. Arnold
Fabian M. Arnold
MWMiriam Sarah Weber
Miriam Sarah Weber
IGImre Gonda
Imre Gonda
MGMarc J. Gallenito
Marc J. Gallenito
SASophia Adenau
Sophia Adenau
MSMarkus A. Seeger
Markus A. Seeger

21 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
CHCedric A. J. Hutter
Cedric A. J. Hutter
MTM. Hadi Timachi
M. Hadi Timachi
LHLea M. Hürlimann
Lea M. Hürlimann
IZIwan Zimmermann
Iwan Zimmermann
PEPascal Egloff
Pascal Egloff
MSMarkus A. Seeger
Markus A. Seeger
ABC exporters harness the energy of ATP to pump substrates across membranes. Extracellular gate opening and closure are key steps of the transport cycle, but the underlying mechanism is poorly understood. Here, we generated a synthetic single domain antibody (sybody) that recognizes the heterodimeric ABC exporter TM287/288 exclusively in the presence of ATP, which was essential to solve a 3.2 Å crystal structure of the outward-facing transporter. The sybody binds to an extracellular wing and strongly inhibits ATPase activity by shifting the transporter’s conformational equilibrium towards the outward-facing state, as shown by double electron-electron resonance (DEER). Mutations that facilitate extracellular gate opening result in a comparable equilibrium shift and strongly reduce ATPase activity and drug transport. Using the sybody as conformational probe, we demonstrate that efficient extracellular gate closure is required to dissociate the NBD dimer after ATP hydrolysis to reset the transporter back to its inward-facing state.

22 April 2019 in Nature Methods
Verified
Journal Article
Closed access
PDF file
PEPascal Egloff
Pascal Egloff
IZIwan Zimmermann
Iwan Zimmermann
FAFabian M. Arnold
Fabian M. Arnold
CHCedric A. J. Hutter
Cedric A. J. Hutter
DMDamien Morger
Damien Morger
MSMarkus A. Seeger
Markus A. Seeger

7 March 2022 in EMBO Reports
Verified
Journal Article
Open access
JWJustin D Walter
Justin D Walter
MSMelanie Scherer
Melanie Scherer
CHCedric A J Hutter
Cedric A J Hutter
AGAlisa A Garaeva
Alisa A Garaeva
IZIwan Zimmermann
Iwan Zimmermann
MSMarkus A Seeger
Markus A Seeger
The ongoing COVID‐19 pandemic represents an unprecedented global health crisis. Here, we report the identification of a synthetic nanobody (sybody) pair, Sb#15 and Sb#68, that can bind simultaneously to the SARS‐CoV‐2 spike RBD and efficiently neutralize pseudotyped and live viruses by interfering with ACE2 interaction. Cryo‐EM confirms that Sb#15 and Sb#68 engage two spatially discrete epitopes, influencing rational design of bispecific and tri‐bispecific fusion constructs that exhibit up to 100‐ and 1,000‐fold increase in neutralization potency, respectively. Cryo‐EM of the sybody‐spike complex additionally reveals a novel up‐out RBD conformation. While resistant viruses emerge rapidly in the presence of single binders, no escape variants are observed in the presence of the bispecific sybody. The multivalent bispecific constructs further increase the neutralization potency against globally circulating SARS‐CoV‐2 variants of concern. Our study illustrates the power of multivalency and biparatopic nanobody fusions for the potential development of therapeutic strategies that mitigate the emergence of new SARS‐CoV‐2 escape mutants.

19 January 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MDMattia Deluigi
Mattia Deluigi
LMLena Morstein
Lena Morstein
MSMatthias Schuster
Matthias Schuster
CKChristoph Klenk
Christoph Klenk
LMLisa Merklinger
Lisa Merklinger
APAndreas Plückthun
Andreas Plückthun
α-adrenergic receptors (αARs) are G protein-coupled receptors that regulate vital functions of the cardiovascular and nervous systems. The therapeutic potential of αARs, however, is largely unexploited and hampered by the scarcity of subtype-selective ligands. Moreover, several aminergic drugs either show off-target binding to αARs or fail to interact with the desired subtype. Here, we report the crystal structure of human α1BAR bound to the inverse agonist (+)-cyclazosin, enabled by the fusion to a DARPin crystallization chaperone. The α1BAR structure allows the identification of two unique secondary binding pockets. By structural comparison of α1BAR with α2ARs, and by constructing α1BAR-α2CAR chimeras, we identify residues 3.29 and 6.55 as key determinants of ligand selectivity. Our findings provide a basis for discovery of α1BAR-selective ligands and may guide the optimization of aminergic drugs to prevent off-target binding to αARs, or to elicit a selective interaction with the desired subtype.

1 April 2015 in Protein Expression and Purification
Verified
Journal Article
Closed access
PEPascal Egloff
Pascal Egloff
MDMattia Deluigi
Mattia Deluigi
PHPhilipp Heine
Philipp Heine
SBStefanie Balada
Stefanie Balada
APAndreas Plückthun
Andreas Plückthun